Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2019 to Jul 2024
Non-GAAP Net Income of $22 Million, 34% Increase Over Third Quarter 2008
EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today reported its financial results for the third quarter 2009. Global Nexavar net sales as reported by Onyx's collaborator Bayer HealthCare Pharmaceuticals, or Bayer, were $229.2 million for the third quarter 2009, a 27% increase compared to $180.9 million in the same period in 2008. Onyx and Bayer are marketing and developing Nexavar® (sorafenib) tablets, an anticancer therapy currently approved for the treatment of liver cancer and advanced kidney cancer in the U.S., European Union, Japan and other territories.
Onyx reported non-GAAP net income of $22.2 million, or $0.35 per diluted share, for the third quarter 2009 compared to non-GAAP net income of $16.6 million, or $0.29 per diluted share, for the same period in 2008. Non-GAAP net income excludes employee stock-based compensation expense, non-cash imputed interest expense related to the application of Accounting Standards Codification ("ASC") Subtopic 470-20 (formerly known as Financial Accounting Standards Board Staff Position, or FSP APB, 14-1), acquisition related transaction costs and a payment to BTG International Limited in connection with the achievement of a development milestone in the ONX 0801 program. Net income for the third quarter 2009 reflected growth in Nexavar sales and lower Nexavar commercial expenses, offset by expanded clinical development efforts, lower investment income and interest expense on the convertible senior notes issued in August 2009. On a GAAP basis, Onyx reported net income of $8.2 million, or $0.14 per diluted share, for the third quarter 2009 compared to net income of $12.2 million, or $0.21 per diluted share, in the same period in 2008. A description of the non-GAAP calculations and reconciliation to comparable GAAP measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income."
"Delivering another quarter of strong financial performance points to our success in building Nexavar as an oncology blockbuster and demonstrates our commitment to executing on our strategic priorities," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "As the next step in our plans to grow the company strategically, we recently announced our intention to acquire Proteolix Inc., a leader in the science of proteasome inhibition. Through continued investigation of Nexavar in a broad array of additional tumor types and investment in a growing number of pipeline candidates, we are creating multiple opportunities for additional value creation."
Revenue from Collaboration Agreement
For the third quarter 2009, Onyx reported revenue from its Nexavar collaboration agreement of $69.1 million compared to $50.8 million for the same period in 2008. The 36% increase in revenue from collaboration agreement between periods resulted from an increase in Nexavar sales and royalty revenue and a decrease in Nexavar commercial expenses.
Operating Expenses
Onyx recorded research and development expenses of $35.6 million in the third quarter 2009, compared to $21.8 million for the same period in 2008. Higher research and development expenses in the third quarter 2009 were primarily due to planned increases in the development program for Nexavar across additional tumor types, such as thyroid, colorectal and adjuvant liver cancer and Onyx's costs to further develop ONX 0801, including a milestone payment of $7.0 million to BTG International Limited. Selling, general and administrative expenses were $23.4 million in the third quarter 2009, compared to $19.3 million for the same period in 2008. Higher selling, general and administrative expenses were primarily due to headcount-related expenses to support Onyx's growth.
Investment Income
Investment income was $1.0 million for the third quarter 2009 compared to $2.8 million in the same period in 2008. The decrease was primarily due to lower effective interest rates as a result of market conditions as well as a change in the asset allocation of Onyx's investment portfolio.
Interest Expense
Interest expense of $2.3 million for the third quarter 2009 relates to the 4.0% convertible senior notes due 2016 issued in August 2009, and includes non-cash imputed interest expense of $1.0 million as a result of the application of ASC Subtopic 470-20 (formerly known as FSP APB 14-1).
Cash, Cash Equivalents and Marketable Securities
At September 30, 2009, cash, cash equivalents, and current and noncurrent marketable securities were $843.1 million, compared to $458.0 million at December 31, 2008. This increase was primarily due to net proceeds of debt and equity financings in August 2009 and cash generated from operations.
Nine-Month Results
Nexavar net sales, as recorded by Bayer, were $608.3 million and $501.3 million for the nine months ended September 30, 2009 and 2008, respectively. Non-GAAP net income for the nine months ended September 30, 2009 was $45.6 million, or $0.73 per diluted share, compared to non-GAAP net income of $45.9 million, or $0.81 per diluted share for the same period in 2008, excluding employee stock-based compensation expense, non-cash imputed interest expense related to the application of ASC Subtopic 470-20 (formerly known as FSP APB 14-1), acquisition related transaction costs and a payment to BTG International Limited in connection with the achievement of a development milestone in the ONX 0801 program. A description of the non-GAAP calculations is provided below in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income." For the nine months ended September 30, 2009, on a GAAP basis Onyx recorded net income of $21.7 million, or $0.37 per diluted share, compared with a net income of $32.1 million, or $0.57 per diluted share, for the same period in 2008.
Management Conference Call Today
Onyx will host a teleconference and webcast to provide a general business overview and discuss financial results. The event will begin at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on November 3, 2009. The live webcast will be available at:
http://www.onyx-pharm.com/view.cfm/32/Event-Calendar
or by dialing 847-619-6547 and using the passcode 25674242. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 25674242 approximately one hour after the teleconference concludes. The replay will be available through December 3, 2009.
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit http://www.onyx-pharm.com/.
Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.
This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding sales trends and commercial activities, the timing, progress and results of clinical development, regulatory filings and actions and Onyx's anticipated acquisition of Proteolix, Inc. and its lead product candidate, carfilzomib. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: Nexavar being our only approved product; competition; failures or delays in our clinical trials; dependence on our collaborative relationship with Bayer; market acceptance and the rate of adoption of our products; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; the indebtedness incurred through the sale of our 4.0% convertible senior notes due 2016; product liability risks; and the consummation and anticipated benefits of the proposed acquisition of Proteolix. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission, under the heading "Risk Factors" for a more detailed description of these and other risks, as well as the company's subsequent quarterly reports on Form 10Q. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
(See attached tables.)
ONYX PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(unaudited)
Three Months
Ended Nine Months Ended
September 30, September 30,
-------------- ------------------
2009 2008 2009 2008
---- ---- ---- ----
Revenue:
Revenue from collaboration
agreement $69,137 $50,766 $183,074 $144,693
------- ------- -------- --------
Total operating revenue 69,137 50,766 183,074 144,693
Operating expenses:
Research and
development (1) 35,635 21,792 92,478 63,845
Selling, general and
administrative (1) 23,440 19,319 68,899 58,985
------ ------ ------ ------
Total operating expenses 59,075 41,111 161,377 122,830
------ ------ ------- -------
Income from operations 10,062 9,655 21,697 21,863
Investment income 1,015 2,763 3,108 10,696
Interest expense (2,255) - (2,255) -
------ ----- ------ -----
Income before provision
for income taxes 8,822 12,418 22,550 32,559
Provision for income taxes 589 175 878 424
--- --- --- ---
Net income $8,233 $12,243 $21,672 $32,135
====== ======= ======= =======
Net income per share:
Basic $0.14 $0.22 $0.37 $0.58
===== ===== ===== =====
Diluted (2) $0.14 $0.21 $0.37 $0.57
===== ===== ===== =====
Shares used in
computing net income
per share:
Basic 60,248 56,197 58,201 55,755
====== ====== ====== ======
Diluted (2) 60,624 57,194 58,511 56,773
====== ====== ====== ======
(1) Includes employee
stock-based compensation
charges of:
Research and development $517 $694 $2,286 $2,083
Selling, general, and
administrative 4,455 3,646 12,647 11,726
----- ----- ------ ------
Total employee stock-
based compensation $4,972 $4,340 $14,933 $13,809
====== ====== ======= =======
(2) Computation of
diluted net income
per share:
Net income $8,233 $12,243 $21,672 $32,135
Add: Interest and
issuance costs related
to dilutive convertible
senior notes (3) - - - -
----- ----- ----- -----
Net income - diluted $8,233 $12,243 $21,672 $32,135
====== ======= ======= =======
Basic shares 60,248 56,197 58,201 55,755
Dilutive effect of
options and
restricted stock 376 997 310 1,018
Dilutive effect of
convertible senior
notes (3) - - - -
----- ----- ----- -----
Diluted shares 60,624 57,194 58,511 56,773
====== ====== ====== ======
(3) Under the "if-converted" method, potential common shares related
to the Company's convertible senior notes were not included in diluted
net income per share for the three and nine months ended September 30,
2009 because their effect would be anti-dilutive.
ONYX PHARMACEUTICALS, INC.
CALCULATION OF REVENUE FROM COLLABORATION AGREEMENT
(In thousands, unaudited)
Three Months Nine Months
Ended September Ended September
30, 30,
---------------- ----------------
2009 2008 2009 2008
---- ---- ---- ----
Nexavar product revenue, net
(as recorded by Bayer) $229,243 $180,887 $608,295 $501,303
======== ======== ======== ========
Revenue subject to
profit sharing (as
recorded by Bayer) $199,774 $168,141 $548,093 $476,584
Combined cost of goods sold,
distribution, selling, general
and administrative expenses 76,309 79,362 222,531 222,200
------ ------ ------- -------
Combined collaboration
commercial profit $123,465 $88,779 $325,562 $254,384
======== ======= ======== ========
Onyx's share of
collaboration commercial
profit $61,732 $44,390 $162,781 $127,192
Reimbursement of Onyx's
shared marketing expenses 5,342 5,484 16,079 15,771
Royalty revenue 2,063 892 4,214 1,730
----- --- ----- -----
Revenue from
collaboration
agreement $69,137 $50,766 $183,074 $144,693
======= ======= ======== ========
ONYX PHARMACEUTICALS, INC.
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME
(In thousands, except per share amounts)
(unaudited)
Three Months Nine Months
Ended Ended
September 30, September 30,
-------------- -------------
2009 2008 2009 2008
---- ---- ---- ----
GAAP net income per share - basic $0.14 $0.22 $0.37 $0.58
GAAP net income per share - diluted (4) $0.14 $0.21 $0.37 $0.57
GAAP net income $8,233 $12,243 $21,672 $32,135
Non-GAAP adjustments:
Employee stock-based compensation 4,972 4,340 14,933 13,809
Imputed interest related to the
application of ASC 470-20 1,027 - 1,027 -
Acquisition related transaction costs 1,011 - 1,011 -
Milestone payments 7,000 - 7,000 -
----- ----- ----- -----
Non-GAAP net income (5) $22,243 $16,583 $45,643 $45,944
======= ======= ======= =======
Computation of non-GAAP
diluted net income
Non-GAAP net income (5) $22,243 $16,583 $45,643 $45,944
Add:
Interest and issuance costs related to
dilutive convertible senior notes (6) 1,228 - 1,228 -
----- ----- ----- -----
Non-GAAP net income - diluted (5) $23,471 $16,583 $46,871 $45,944
======= ======= ======= =======
Computation of non-GAAP diluted shares
Basic shares 60,248 56,197 58,201 55,755
Adjustments for dilutive effects:
Dilutive effect of options
and restricted stock 376 997 310 1,018
Dilutive effect of
convertible senior notes
(6) 5,801 - 5,801 -
----- ----- ----- -----
Non-GAAP diluted shares (5) 66,425 57,194 64,312 56,773
====== ====== ====== ======
Non-GAAP net income per share (5) $0.37 $0.30 $0.78 $0.82
Non-GAAP net income per
share - diluted (5) $0.35 $0.29 $0.73 $0.81
(4) Under the "if-converted" method, dilutive potential common shares
related to the Company's convertible senior notes were not included in
GAAP diluted net income per share for the three and nine months ended
September 30, 2009 because their effect would be anti-dilutive.
(5) This press release includes the following non-GAAP financial measures:
non-GAAP net income and non-GAAP net income per share. The foregoing table
reconciles these non-GAAP measures to the most comparable financial
measures calculated in accordance with GAAP.
Onyx management uses these non-GAAP financial measures to monitor and evaluate our operating results and trends on an on-going basis and internally for operating, budgeting and financial planning purposes. Onyx management believes the non-GAAP information is useful for investors by offering them the ability to better identify trends in our business and better understand how management evaluates the business. These non-GAAP measures have limitations, however, because they do not include all items of income and expense that affect Onyx. These non-GAAP financial measures that management uses are not prepared in accordance with, and should not be considered in isolation of, or an as alternative to, measurements required by GAAP.
These non-GAAP financial measures exclude the following items from GAAP net income and diluted EPS:
Employee stock-based compensation: Onyx management excludes the effects of employee stock-based compensation because of varying available valuation methodologies, subjective assumptions and the variety of award types; such exclusion facilitates comparisons of Onyx's operating results to peer companies.
Imputed interest related to the application of ASC Subtopic 470-20: Onyx management excludes the effects of imputed interest related to the Company's convertible senior notes due 2016 because this expense is non-cash; such exclusion facilitates comparisons of Onyx's cash operating results to peer companies.
Milestone payments and acquisition related transaction costs: Onyx management excludes the effects of milestone payments and acquisition related transaction costs as they do not relate to the normal and recurring transactions of our business; such exclusions allow for a better representation of the ongoing economics of the business, facilitates comparison to peer companies and is reflective of how Onyx management internally manages the business.
(6) Under the "if-converted" method, potential common shares related to
the Company's convertible senior notes were included in non-GAAP net
income per share - diluted for the three and nine months ended September
30, 2009 because their effect is dilutive.
ONYX PHARMACEUTICALS, INC.
CONDENSED BALANCE SHEETS
(In thousands)
Sep. 30, Dec. 31,
2009 2008
(unaudited) (7)
------------ --------
Assets
Cash, cash equivalents and
marketable securities $804,670 $418,424
Other current assets 58,833 43,635
------ ------
Total current assets 863,503 462,059
Property and equipment, net 3,124 3,363
Marketable securities,
non-current 38,410 39,622
Other assets 9,014 4,723
----- -----
Total assets $914,051 $509,767
======== ========
Liabilities and stockholders'
equity
Current liabilities 22,888 33,304
Convertible senior notes due
2016 141,559 -
Other long-term liabilities 986 1,263
Stockholders' equity 748,618 475,200
------- -------
Total liabilities and
stockholders' equity $914,051 $509,767
======== ========
(7) Derived from the audited financial statements included in the
Company's Annual Report on Form 10-K for the year-ended December 31,
2008.
DATASOURCE: Onyx Pharmaceuticals, Inc.
CONTACT: Julie Wood, Vice President, Investor Relations of Onyx
Pharmaceuticals, Inc., +1-510-597-6505
Web Site: http://www.onyx-pharm.com/